$CELC
Celcuity Inc.

2023 Q1 Form 10-K Financial Statement

#000149315223008724 Filed on March 23, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.269M $1.035M $4.102M
YoY Change 56.42% 24.74% 57.88%
% of Gross Profit
Research & Development $11.28M $10.60M $35.29M
YoY Change 68.43% 93.12% 37.0%
% of Gross Profit
Depreciation & Amortization $43.94K $48.94K $210.9K
YoY Change -21.53% -22.35% -30.45%
% of Gross Profit
Operating Expenses $12.55M $11.64M $39.39M
YoY Change 67.13% 84.14% 38.92%
Operating Profit -$12.55M -$39.39M
YoY Change 67.13% 38.92%
Interest Expense $1.242M $57.86K $2.106M
YoY Change -390.98% -113.37% -268.61%
% of Operating Profit
Other Income/Expense, Net $609.1K -$978.9K
YoY Change -21.64%
Pretax Income -$11.94M -$11.58M -$40.37M
YoY Change 50.46% 71.49% 36.36%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$11.94M -$11.58M -$40.37M
YoY Change 50.46% 71.49% 36.36%
Net Earnings / Revenue
Basic Earnings Per Share -$0.55 -$2.64
Diluted Earnings Per Share -$0.55 -$0.69 -$2.62
COMMON SHARES
Basic Shares Outstanding 21.69M shares 15.46M shares 15.42M shares
Diluted Shares Outstanding 21.68M shares 15.42M shares

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $157.5M $168.6M $168.6M
YoY Change 101.13% 100.02% 100.02%
Cash & Equivalents $33.64M $24.57M $24.57M
Short-Term Investments $123.8M $144.0M $144.0M
Other Short-Term Assets $6.583M $6.399M $6.399M
YoY Change 589.04% 734.52% 734.52%
Inventory
Prepaid Expenses $6.525M $6.344M
Receivables
Other Receivables
Total Short-Term Assets $164.1M $175.2M $175.2M
YoY Change 106.56% 105.26% 105.26%
LONG-TERM ASSETS
Property, Plant & Equipment $223.3K $260.3K $506.6K
YoY Change -54.04% -16.69% -8.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $775.3K $506.6K $506.6K
YoY Change 59.52% -8.62% -8.62%
TOTAL ASSETS
Total Short-Term Assets $164.1M $175.2M $175.2M
Total Long-Term Assets $775.3K $506.6K $506.6K
Total Assets $164.9M $175.7M $175.7M
YoY Change 106.27% 104.52% 104.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.570M $2.627M $2.627M
YoY Change 20.13% 74.31% 74.31%
Accrued Expenses $3.040M $4.060M $2.005M
YoY Change 116.28% 405.71% 134.84%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $980.00 $2.450K $2.450K
YoY Change -83.28% -58.12% -58.12%
Total Short-Term Liabilities $5.806M $6.882M $6.882M
YoY Change 63.51% 174.64% 174.64%
LONG-TERM LIABILITIES
Long-Term Debt $35.48M $34.98M $34.98M
YoY Change 139.33% 139.15% 139.15%
Other Long-Term Liabilities $364.0K $61.00K $61.00K
YoY Change 2274.17% -1.25% -1.25%
Total Long-Term Liabilities $35.84M $35.04M $35.04M
YoY Change 141.54% 138.56% 138.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.806M $6.882M $6.882M
Total Long-Term Liabilities $35.84M $35.04M $35.04M
Total Liabilities $41.65M $41.93M $41.93M
YoY Change 126.47% 143.81% 143.81%
SHAREHOLDERS EQUITY
Retained Earnings -$108.2M -$96.30M
YoY Change 72.18%
Common Stock $21.94K $21.67K
YoY Change 45.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $123.2M $133.8M $133.8M
YoY Change
Total Liabilities & Shareholders Equity $164.9M $175.7M $175.7M
YoY Change 106.27% 104.52% 104.52%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$11.94M -$11.58M -$40.37M
YoY Change 50.46% 71.49% 36.36%
Depreciation, Depletion And Amortization $43.94K $48.94K $210.9K
YoY Change -21.53% -22.35% -30.45%
Cash From Operating Activities -$12.87M -$9.479M -$36.01M
YoY Change 116.88% 54.79% 77.28%
INVESTING ACTIVITIES
Capital Expenditures $6.987K $112.1K $158.8K
YoY Change -160.03% -1227.26% -293.86%
Acquisitions
YoY Change
Other Investing Activities $21.87M -$143.9M -$143.9M
YoY Change -28774706.0%
Cash From Investing Activities $21.87M -$144.0M -$144.0M
YoY Change -187965.56% 1448441.95% 176843.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $67.95K 120.6M $120.3M
YoY Change -246.79% 225188.94% 29.32%
NET CHANGE
Cash From Operating Activities -$12.87M -9.479M -$36.01M
Cash From Investing Activities $21.87M -144.0M -$144.0M
Cash From Financing Activities $67.95K 120.6M $120.3M
Net Change In Cash $9.068M -32.91M -$59.71M
YoY Change -251.36% 441.28% -182.2%
FREE CASH FLOW
Cash From Operating Activities -$12.87M -$9.479M -$36.01M
Capital Expenditures $6.987K $112.1K $158.8K
Free Cash Flow -$12.87M -$9.591M -$36.17M
YoY Change 117.43% 56.87% 78.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001603454
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
usd
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
usd
CY2022 CELC Issuance Of Common Stock Licensing Agreement
IssuanceOfCommonStockLicensingAgreement
usd
CY2022 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
usd
CY2021 us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
usd
CY2021 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
usd
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
usd
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
CY2022 CELC Proceeds From Follow On Offering Net Of Underwriting Discounts And Offering Costs
ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts
usd
CY2021 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
usd
CY2022 us-gaap Stock Issued1
StockIssued1
usd
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
usd
CY2022Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
usd
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
usd
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
usd
CY2022Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
usd
CY2022Q4 CELC Lessee Operating Lease Liability Amount Representing Services
LesseeOperatingLeaseLiabilityAmountRepresentingServices
usd
CY2022Q4 CELC Notes Payable Final Fee
NotesPayableFinalFee
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021Q4 CELC Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Irc174 Expenditures
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures
usd
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-38207
CY2022 dei Entity Registrant Name
EntityRegistrantName
Celcuity Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2863566
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
16305 36th
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Avenue North
CY2022 dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 100
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Minneapolis
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55446
CY2022 dei City Area Code
CityAreaCode
(763)
CY2022 dei Local Phone Number
LocalPhoneNumber
392-0767
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2022 dei Trading Symbol
TradingSymbol
CELC
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
96109668 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21689425 shares
CY2022 dei Auditor Name
AuditorName
Boulay PLLP
CY2022 dei Auditor Location
AuditorLocation
Minneapolis, Minnesota
CY2022 dei Auditor Firm
AuditorFirmId
542
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24571557 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84286381 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
144015954 usd
CY2022Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
22009 usd
CY2021Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
22009 usd
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
33195 usd
CY2021Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
22144 usd
CY2022Q4 CELC Payroll Tax Receivable
PayrollTaxReceivable
203665 usd
CY2021Q4 CELC Payroll Tax Receivable
PayrollTaxReceivable
298764 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6344157 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
722677 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
175190537 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
85351975 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
260294 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
312444 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
246266 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
241901 usd
CY2022Q4 us-gaap Assets
Assets
175697097 usd
CY2021Q4 us-gaap Assets
Assets
85906320 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2627076 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1507099 usd
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2449 usd
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
5850 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
191749 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
189858 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4060280 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
802893 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6881554 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2505700 usd
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
2449 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
61002 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
61771 usd
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
34983074 usd
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
14625923 usd
CY2022Q4 us-gaap Liabilities
Liabilities
41925630 usd
CY2021Q4 us-gaap Liabilities
Liabilities
17195843 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1120873 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1120873 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
1121 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21667250 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21667250 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14918887 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14918887 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
21667 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
14919 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
230045566 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
124622405 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-96296887 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55926847 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
133771467 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
68710477 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
175697097 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
85906320 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35289548 usd
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25758006 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4101543 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2597909 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
39391091 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
28355915 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-39391091 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-28355915 usd
CY2022 us-gaap Interest Expense
InterestExpense
2106111 usd
CY2021 us-gaap Interest Expense
InterestExpense
1262350 usd
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
1127162 usd
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
13262 usd
CY2021 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-263 usd
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-978949 usd
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1249351 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40370040 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29605266 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-40370040 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-29605266 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.64
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.21
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15418543 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13382553 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
11702270 usd
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
2609935 usd
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
65839 usd
CY2021 CELC Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
18762 usd
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
63420 usd
CY2021 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
78530584 usd
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
38962 usd
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3868 usd
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
289839 usd
CY2021 CELC Stock Issued During Period Value Issuance Of Common Stock Licensing Agreement
StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement
5000000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-29605266 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
68710477 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
68710477 usd
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
4638205 usd
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
171710 usd
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
152412 usd
CY2022 CELC Stock Issued During Period Value Issuance Of Common And Preferred Stock Upon Closing Of Private Placement Offering
StockIssuedDuringPeriodValueIssuanceOfCommonAndPreferredStockUponClosingOfPrivatePlacementOffering
100000000 usd
CY2022 CELC Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Issuance With Private Placement Offering
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering
-4316534 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5175000 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
389763 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-40370040 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
133771467 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
133771467 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-40370040 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-29605266 usd
CY2022 us-gaap Depreciation
Depreciation
210918 usd
CY2021 us-gaap Depreciation
Depreciation
303235 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
4638205 usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2609935 usd
CY2021 CELC Issuance Of Common Stock Licensing Agreement
IssuanceOfCommonStockLicensingAgreement
5000000 usd
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
395757 usd
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
267821 usd
CY2022 us-gaap Paid In Kind Interest
PaidInKindInterest
455074 usd
CY2021 us-gaap Paid In Kind Interest
PaidInKindInterest
300001 usd
CY2022 CELC Increase Decrease In Non Cash Operating Lease Expense
IncreaseDecreaseInNonCashOperatingLeaseExpense
-3243 usd
CY2021 CELC Increase Decrease In Non Cash Operating Lease Expense
IncreaseDecreaseInNonCashOperatingLeaseExpense
-7740 usd
CY2021 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-263 usd
CY2022 us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
142928 usd
CY2022 CELC Increase Decrease In Payroll Tax Receivable
IncreaseDecreaseInPayrollTaxReceivable
-95099 usd
CY2021 CELC Increase Decrease In Payroll Tax Receivable
IncreaseDecreaseInPayrollTaxReceivable
108764 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5621480 usd
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
405637 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1077080 usd
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1305932 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3257387 usd
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
28280 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36008171 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20311940 usd
CY2022 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
143873026 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
158768 usd
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
81898 usd
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
500 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-144031794 usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-81398 usd
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
18762 usd
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
152412 usd
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
63420 usd
CY2022 CELC Proceeds From Employee Stock Purchases
ProceedsFromEmployeeStockPurchases
171710 usd
CY2021 CELC Proceeds From Employee Stock Purchases
ProceedsFromEmployeeStockPurchases
65839 usd
CY2021 CELC Proceeds From Follow On Offering Net Of Underwriting Discounts And Offering Costs
ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts
78530585 usd
CY2022 CELC Proceeds From An Atm Offering Net Of Commision And Offering Costs
ProceedsFromAnATMOfferingNetOfCommisionAndOfferingCosts
4776046 usd
CY2021 CELC Proceeds From An Atm Offering Net Of Commision And Offering Costs
ProceedsFromAnATMOfferingNetOfCommisionAndOfferingCosts
21073 usd
CY2022 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
19509037 usd
CY2021 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
14347939 usd
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
95721786 usd
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
5850 usd
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
5810 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
120325141 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
93041808 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-59714824 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
72648470 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
84286381 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11637911 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24571557 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
84286381 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
1255280 usd
CY2021 us-gaap Interest Paid Net
InterestPaidNet
694528 usd
CY2022 CELC Deferred Financing Costs And Offering And Registration Statement Costs Included In Accounts Payable
DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable
51020 usd
CY2021 CELC Deferred Financing Costs And Offering And Registration Statement Costs Included In Accounts Payable
DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccountsPayable
8123 usd
CY2021 us-gaap Stock Issued1
StockIssued1
964839 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_841_eus-gaap--UseOfEstimates_zJnQjVEdOD57" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zR6g0DM1GSb">Accounting Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management uses estimates and assumptions in preparing these financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates and the difference could be significant. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
24571557 usd
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
84286381 usd
CY2021Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
22144 usd
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
28932 usd
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
26521 usd
CY2022 us-gaap Depreciation
Depreciation
210918 usd
CY2021 us-gaap Depreciation
Depreciation
303235 usd
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
2411 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
144015954 usd
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
33195 usd
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zH6HgjVcwBH1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_860_zE39t8TZWxEb">Risks and Uncertainties</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its initial drug product, gedatolisib, the clinical and commercial success of its diagnostic tests, ability to obtain regulatory approval for gedatolisib and its diagnostic tests, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35289548 usd
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25758006 usd
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
271988 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24571557 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
144015954 usd
CY2022Q3 CELC Deemed Dividend
DeemedDividend
272000 usd
CY2022 CELC Increased Net Loss Per Share Basic And Diluted
IncreasedNetLossPerShareBasicAndDiluted
0.02
CY2022Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
144015954 usd
CY2022Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
71156 usd
CY2022Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
144087110 usd
CY2022Q4 CELC Payroll Tax Receivable
PayrollTaxReceivable
203665 usd
CY2021Q4 CELC Payroll Tax Receivable
PayrollTaxReceivable
298764 usd
CY2022Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
2449 usd
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2449 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
206957 usd
CY2022Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
3023 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
69439 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6344157 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
722677 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1979512 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1820744 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1719218 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1508300 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
260294 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
312444 usd
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
929216 usd
CY2021Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
438477 usd
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
38967 usd
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
34455 usd
CY2022Q4 CELC Accrued Clinical Trial Expense
AccruedClinicalTrialExpense
2246573 usd
CY2021Q4 CELC Accrued Clinical Trial Expense
AccruedClinicalTrialExpense
138788 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
845524 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
191173 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4060280 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
802893 usd
CY2020Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
197211 usd
CY2021Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
193517 usd
CY2022Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
195437 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
246266 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
252751 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
191749 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
61002 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
276396 usd
CY2022Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
3023 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
23645 usd
CY2022Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
5 usd
CY2022Q4 CELC Amount Representing Services
AmountRepresentingServices
-569 usd
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
30000000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
65000000 shares
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
252751 usd
CY2022Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
2449 usd
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M18D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080 pure
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y3M18D
CY2022Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.010 pure
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
197767 usd
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
185379 usd
CY2022 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
5786 usd
CY2021 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
5786 usd
CY2022 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
39 usd
CY2021 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
79 usd
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
81077 usd
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
79477 usd
CY2022 us-gaap Lease Cost
LeaseCost
284669 usd
CY2021 us-gaap Lease Cost
LeaseCost
270721 usd
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
282086 usd
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
274297 usd
CY2022 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
39 usd
CY2021 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
79 usd
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
5850 usd
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
5810 usd
CY2022 CELC Cash Paid For Operating And Finance Leases
CashPaidForOperatingAndFinanceLeases
287975 usd
CY2021 CELC Cash Paid For Operating And Finance Leases
CashPaidForOperatingAndFinanceLeases
280186 usd
CY2022Q4 us-gaap Contractual Obligation
ContractualObligation
2300000 usd
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14918887 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21667250 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1120873 shares
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
7266102 usd
CY2022Q3 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2025-09-19
CY2022Q3 CELC Estimated Incremental Fair Value Of Warrants
EstimatedIncrementalFairValueOfWarrants
271988 usd
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q4 CELC Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Not Yet Recognized Next Twelve Months
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedNextTwelveMonths
3347255 usd
CY2022Q4 CELC Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Not Yet Recognizedwithin Two Years
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedwithinTwoYears
2161383 usd
CY2022Q4 CELC Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Not Yet Recognizedwithin Three Years
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedwithinThreeYears
1405076 usd
CY2022Q4 CELC Employee Service Share Based Compensation Non Vested Awards Compensation Cost Not Yet Recognized Within Four Years
EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears
365245 usd
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
7278959 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
13048000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
19300000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
500000 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
4638205 usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2609935 usd
CY2022Q4 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
100000000 usd
CY2022Q3 CELC Prepayment Fee Percentage
PrepaymentFeePercentage
0.030 pure
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
35000000 usd
CY2021Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
15000000 usd
CY2022Q4 CELC Payment In Kind Interest Debt
PaymentInKindInterestDebt
755075 usd
CY2021Q4 CELC Payment In Kind Interest Debt
PaymentInKindInterestDebt
300001 usd
CY2021Q4 CELC Notes Payable Final Fee
NotesPayableFinalFee
675000 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
707001 usd
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
386578 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
65000 usd
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
962500 usd
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
34983074 usd
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
14625923 usd
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
13408153 usd
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
17877538 usd
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
4469384 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
35755075 usd
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-8478000 usd
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6217000 usd
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-64000 usd
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-49000 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
9543000 usd
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6330000 usd
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-1347000 usd
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-222000 usd
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
346000 usd
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
158000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
103000 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
50000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1419000 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
796000 usd
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
364000 usd
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
319000 usd
CY2022Q4 CELC Deferred Tax Assets Rightofuse Assets
DeferredTaxAssetsRightofuseAssets
52000 usd
CY2021Q4 CELC Deferred Tax Assets Rightofuse Assets
DeferredTaxAssetsRightofuseAssets
51000 usd
CY2022Q4 CELC Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
53000 usd
CY2021Q4 CELC Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
53000 usd
CY2022Q4 CELC Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Irc174 Expenditures
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIRC174Expenditures
3326000 usd
CY2022Q4 CELC Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Startup Expenditures
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures
10333000 usd
CY2021Q4 CELC Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Startup Expenditures
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStartupExpenditures
6966000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7045000 usd
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4915000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
22591000 usd

Files In Submission

Name View Source Status
celc-20221231_cal.xml Edgar Link unprocessable
celc-20221231_def.xml Edgar Link unprocessable
0001493152-23-008724-index-headers.html Edgar Link pending
0001493152-23-008724-index.html Edgar Link pending
0001493152-23-008724.txt Edgar Link pending
0001493152-23-008724-xbrl.zip Edgar Link pending
celc-20221231.xsd Edgar Link pending
ex23-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
form10k_001.jpg Edgar Link pending
form10k_002.jpg Edgar Link pending
form10k_003.jpg Edgar Link pending
form10k_004.jpg Edgar Link pending
form10k_005.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
celc-20221231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
celc-20221231_pre.xml Edgar Link unprocessable
form10-k_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending